{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-011174","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.010246+00:00","generated_at":"2026-05-24T01:30:38.387378+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol","bullets":["Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.","Cash $15.1M at Dec 31, 2024; new $5M line of credit from chairman in March 2025; cash runway through Aug 2025.","NAVIGATE trial: varices incidence reduced 49.3% (p=0.04) in per-protocol for belapectin 2 mg vs placebo.","In US per-protocol patients, varices reduced 68.1% (p=0.02); ITT population did not reach significance.","Additional biomarker data expected Q2 2025; belapectin has FDA Fast Track Designation for MASH cirrhosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-011174","json":"https://secwatch.observer/filing/0001140361-25-011174.json","markdown":"https://secwatch.observer/filing/0001140361-25-011174.md","text":"https://secwatch.observer/filing/0001140361-25-011174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/0001140361-25-011174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/ef20046120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:30:38.387378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}